FrCVCOPD: Influence of Frailty on Cardiovascular Events and Mortality in Patients With COPD.

Sponsor
Azienda Ospedaliero-Universitaria di Modena (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05922202
Collaborator
(none)
300
33.1

Study Details

Study Description

Brief Summary

Observational study on the influence of frailty on cardiovascular risk in COPD.

Condition or Disease Intervention/Treatment Phase
  • Other: Assessment of cardiovascular events, cardiovascular mortality, all-cause mortality, and mortality due to COPD at 12 and 24 months

Detailed Description

The study will investigate the influence that frailty can have on cardiovascular risk in patients with COPD. The project will assess the association between frailty and all-cause mortality, and the relationship between frailty and cardiovascular mortality, by comparing COPD patients living with frailty vs non-frail COPD patients.

The study participants will be outpatients with diagnosis of COPD according to the Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) guidelines (www.goldcopd.org).

The follow up will be at 12 and 24 months.

Study Design

Study Type:
Observational
Anticipated Enrollment :
300 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Influence of Frailty on Cardiovascular Events and Mortality in Patients With Chronic Obstructive Pulmonary Disease (COPD): A Multicentre Observational Study.
Anticipated Study Start Date :
Sep 25, 2023
Anticipated Primary Completion Date :
Sep 25, 2025
Anticipated Study Completion Date :
Jun 30, 2026

Arms and Interventions

Arm Intervention/Treatment
COPD outpatients

Outpatients with COPD. COPD diagnosis confirmed by spirometry and according to Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) guidelines.

Other: Assessment of cardiovascular events, cardiovascular mortality, all-cause mortality, and mortality due to COPD at 12 and 24 months
At 12 and 24 months of follow up, cardiovascular events (including hospital admissions), deaths due to cardiovascular disease, deaths due to all-cause, deaths due to COPD will be recorded in COPD outpatients group.

Outcome Measures

Primary Outcome Measures

  1. Number of cardiovascular events in COPD patients living with frailty vs non-frail COPD. patients. [12 and 24 months]

    Number of cardiovascular events (including hospital admissions for cardiovascular events) at 12 and 24 months in COPD patients living with frailty vs non-frail COPD patients.

Secondary Outcome Measures

  1. All-cause long-term mortality in COPD patients living with frailty vs non-frail COPD patients. [12 and 24 months]

    All-cause long-term mortality at 12 and 24 months in COPD patients living with frailty vs non-frail COPD patients.

  2. Cardiovascular mortality in COPD patients living with frailty vs non-frail COPD patients. [12 and 24 months]

    Long-term cardiovascular mortality at 12 and 24 months in COPD patients living with frailty vs non-frail COPD patients.

  3. Prevalence of frailty in COPD. [Baseline, at 12 and 24 months]

    Prevalence of frailty in COPD.

  4. Deaths due to COPD in COPD patients living with frailty vs non-frail COPD patients. [12 and 24 months]

    Number of deaths due to COPD at 12 and 24 months in COPD patients living with frailty vs non-frail COPD patients.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients with age ≥18 years, with diagnosis of COPD of at least 1 year, in stable condition, without acute exacerbation in the last 30 days and/or all-cause hospitalisation in the last 3 months

  • Smoking history of ≥ 10 pack/years

  • Diagnosis of COPD according to GOLD guidelines (www.goldcopd.org)

  • Individuals able to provide their written informed consent.

Exclusion Criteria:
  • Concurrent diagnosis of asthma

  • Concurrent diagnosis of interstitial lung disease

  • Presence of restrictive pattern on spirometry

  • No history of smoking habit

  • Individuals not able to provide their written informed consent.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Azienda Ospedaliero-Universitaria di Modena

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

Responsible Party:
Alessia Verduri, Dr Alessia Verduri, Azienda Ospedaliero-Universitaria di Modena
ClinicalTrials.gov Identifier:
NCT05922202
Other Study ID Numbers:
  • 6390
First Posted:
Jun 28, 2023
Last Update Posted:
Jun 28, 2023
Last Verified:
Jun 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 28, 2023